Naveris specializes in the development of advanced technologies for early cancer detection, particularly focusing on viral cancers associated with human papillomavirus (HPV). Their flagship product, NavDx®, is a liquid biopsy that employs proprietary methods to conduct highly sensitive blood tests. This innovative approach allows for the detection of HPV-related cancers significantly earlier than traditional imaging techniques or biopsies, thereby enhancing the potential for improved patient outcomes. The technology facilitates non-invasive monitoring of cancer recurrence in patients who are in remission and provides real-time insights into treatment responses.

The company’s core technology revolves around circulating tumor HPV DNA assessments, which are critical for the diagnosis and surveillance of HPV-associated cancers, particularly oropharyngeal carcinoma. Naveris has conducted extensive clinical research to validate the efficacy of their liquid biopsy tests, demonstrating their ability to correlate circulating tumor DNA with clinical outcomes. This research underscores the transformative potential of Naveris' technologies in revolutionizing cancer detection and management, ultimately aiming to improve survival rates and quality of life for patients affected by these diseases.

United States

Naveris has developed blood tests for cancers to enable early diagnosis in the general asymptomatic population, real time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission.

Naveris

Company Details